• Explore /
  • Poster
  • / Lanreotide depot/autogel (LAN) vs. placebo (PBO) for carcinoid syndrome (CS) in patients with neuroendocrine tumors (NETs): Subgroup analysis of the ELECT study.

Lanreotide depot/autogel (LAN) vs. placebo (PBO) for carcinoid syndrome (CS) in patients with neuroendocrine tumors (NETs): Subgroup analysis of the ELECT study.

Abstract Poster

Authors

null

Aaron Vinik

Eastern Virginia Medical School, Norfolk, VA

Aaron Vinik , Edward M. Wolin , Helene Audry , Edda Gomez-Panzani , George A. Fisher

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Neuroendocrine/Carcinoid

Clinical Trial Registration Number

NCT00774930

Citation

J Clin Oncol 33, 2015 (suppl; abstr 4103)

DOI

10.1200/jco.2015.33.15_suppl.4103

Abstract #

4103

Poster Bd #

214

Abstract Disclosures

Similar Posters

Poster

2018 Gastrointestinal Cancers Symposium

Lanreotide for the prolonged control of carcinoid syndrome (CS) in somatostatin analog (SSA)-naïve or experienced patients.

Lanreotide for the prolonged control of carcinoid syndrome (CS) in somatostatin analog (SSA)-naïve or experienced patients.

First Author: Edward M. Wolin

First Author: George A. Fisher Jr.

First Author: Rodney F. Pommier

First Author: Lowell Anthony